Health News: Suspected Cause Of Huntington's Is Actually A Defense Mechanism That May Lead To New Treatment, Courtesy
June 27, 2017 | Mitoconix Bio, a budding Israeli biopharmaceutical startup focused on therapies for neurological diseases, has secured $20 million in a Series A funding round led by Remiges Ventures. Founded in 2016 at the FutuRx biotechnology incubator, Mitoconix Bio has developed a unique method of slowing neuro-degenerative diseases using drugs which improve mitochondrial functioning. The company has an exclusive license for the technology behind its lead drug, which was developed by founder Daria Mochly-Rosen at Stanford University. The funding will be used to advance Mitoconix’s treatment of Huntington’s disease.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Israeli Pineapple-Based Burn Therapy Treating Injured US Troops
October 02, 2023

AI Can Predict Future Heart Attacks By Analyzing CT Scans
October 01, 2023

Israeli Startups Create Powerful Drone-Detecting Software
September 28, 2023

Model Sees Daylight As Boost For Hospitalized Patients’ Health
September 28, 2023
Facebook comments